title: No Resistance to Penicillin, Cefuroxime, Cefotaxime, or Vancomycin in Pneumococcal Pneumonia.
abstract: OBJECTIVE
  Group B Streptococcus is a primary source of pneumonia, which is a leading cause of death worldwide. During the last few decades, there has been news of growing antibiotic resistance in group B streptococci to penicillin and different antibiotic agents. This clinical study retrospectively analyzes antimicrobial resistance in inpatients who were diagnosed with group B streptococcal pneumonia.
  
  
  METHODS
  All of the required information from inpatients who were identified to have group B streptococcal pneumonia was sourced from the database at the Department of Internal Medicine of HELIOS Clinic Wuppertal, Witten/Herdecke University, in Germany, from 2004-2014. Antimicrobial susceptibility testing was performed for the different antimicrobial agents that were regularly administered to these inpatients.
  
  
  RESULTS
  Sixty-six inpatients with a mean age of 63.3 ± 16.1 years (45 males [68.2%, 95% CI 60.0%-79.4%] and 21 females [31.8%, 95% CI 20.6%-43.0%]) were detected to have group B streptococcal pneumonia within the study period from January 1, 2004, to August 12, 2014. Group B Streptococcus had a high resistance rate to gentamicin (12.1%), erythromycin (12.1%), clindamycin (9.1%), and co-trimoxazole (3.0%), but it was not resistant to penicillin, cefuroxime, cefotaxime, or vancomycin (P < 0.0001).
  
  
  CONCLUSIONS
  No resistance to penicillin, cefuroxime, cefotaxime, or vancomycin was detected among inpatients with pneumonia caused by group B streptococci.
authors.affiliation: 1. Witten/Herdecke University, Witten, Department of Internal Medicine, Division of Pulmonary, Allergy, and Sleep Medicine, HELIOS Clinic Wuppertal, Germany.
authors.forename: Josef
authors.initials: J
authors.lastname: Yayan
authors.affiliation: 2. Witten/Herdecke University, Witten, Institute of Medical Laboratory Diagnostics, Center for Clinical and Translational Research, HELIOS Clinic Wuppertal, Germany.
authors.forename: Beniam
authors.initials: B
authors.lastname: Ghebremedhin
authors.affiliation: 1. Witten/Herdecke University, Witten, Department of Internal Medicine, Division of Pulmonary, Allergy, and Sleep Medicine, HELIOS Clinic Wuppertal, Germany.
authors.forename: Kurt
authors.initials: K
authors.lastname: Rasche
mesh_terms: D000368:Aged; D002439:Cefotaxime / Q000494:pharmacology; D002444:Cefuroxime / Q000494:pharmacology; D018550:Cephalosporin Resistance; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010403:Penicillin Resistance; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy* / Q000382:microbiology; D012189:Retrospective Studies; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013292:Streptococcus agalactiae / Q000187:drug effects / Q000302:isolation & purification; D020713:Vancomycin Resistance
chemical_list: D002439:Cefotaxime; D002444:Cefuroxime
keywords: Antibiotic; Group B Streptococcus; Pneumonia; Resistance; Sensitivity